West Pharmaceutical Services, Inc. · WST · FY2026 Q1 · Calendar Q2 2026

West Pharma raises guidance as GLP-1 and Annex 1 drive growth

The quarter supports a constructive view of West Pharma's growth trajectory: demand for GLP-1-related components, biologics and Annex 1 upgrades drove a guidance increase. The next test is whether capacity expansion and operational improvements can sustain growth and margins as commodity and regulatory risks persist.

Why did WST rise 12.9% after beating EPS estimates in FY2026 Q1?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $26.46B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.13 Consensus $1.68
EPS surprise +26.8% Reported versus consensus
Reported revenue $844.9M Consensus $780.3M
Revenue surprise +8.3% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +12.9% Event window
SPY move -0.4% Same window
Abnormal move +13.2% Stock minus SPY
Volume 3.3× Versus trailing sessions
Subsequent drift +2.1% Up to 20 sessions
WSTSPY benchmark

Ask FN2 about WST FY2026 Q1

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

West Pharma moved from maintained guidance in the prior quarter to raised full-year guidance. The current analysis also highlights a fully operational Dublin West Vantage site, a $1 billion share-repurchase authorization, and an expected 200-basis-point revenue contribution from Annex 1 and HVP conversion initiatives.

Guidance delta

Management raised full-year guidance to 7%-9% organic revenue growth and adjusted EPS of $8.40-$8.75, from the prior quarter's 5%-7% organic growth and approximately 10% EPS-growth outlook.

Key takeaways

  • Q1 results beat expectations, with growth led by HVP components, particularly GLP-1 elastomers.
  • Annex 1 upgrades, biologics demand, and the Dublin site support the capacity and growth plan.
  • Operational excellence is being extended across European and U.S. sites, while execution and commodity risks remain.

Management priorities

  • Scale Dublin drug-handling capacity and broader contract manufacturing.
  • Advance Annex 1 conversion projects and HVP component upgrades.
  • Extend operational excellence, develop delivery devices, and expand in Asia Pacific.

Follow WST with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
WST REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $739M Q4 '23 actual $732M, miss Q1 '24 estimate $671M Q1 '24 actual $695M, beat Q2 '24 estimate $729M Q2 '24 actual $702M, miss Q3 '24 estimate $740M Q3 '24 actual $747M, beat Q2 '25 estimate $726M Q2 '25 actual $766M, beat Q3 '25 estimate $786M Q3 '25 actual $804M, beat Q4 '25 estimate $795M Q4 '25 actual $805M, beat Q1 '26 estimate $780M Q1 '26 actual $845M, beat Q2 '26 estimate $840M Q2 '26 actual $872M, beat Q3 '26 estimate $827M Q3 '26 actual $874M, beat Q4 '26 estimate $825M Q1 '27 estimate $859M Q2 '27 estimate $894M Q3 '27 estimate $930M
Show less

Analyst Consensus ?

ConsensusBuy16 ratings
Bullish1381.3%
Neutral212.5%
Bearish16.2%

Analyst 52W Price Targets

$390.3Current
$310Low
$384.86Average
$475High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
TD Cowen Buy BuyMaintainOct 30, 2026
Evercore ISI Group Outperform OutperformMaintainOct 30, 2026
Citigroup Buy BuyMaintainOct 30, 2026
Barclays Overweight OverweightMaintainOct 30, 2026
Morgan Stanley Overweight Equal WeightUpgradeSep 22, 2026
Show 11 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $390.3. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesDavid Windley$475$412.62 +21.7%Nov 2, 2026
BarclaysLuke Sergott$440$372.64 +12.7%Oct 7, 2026
Morgan StanleyKallum Titchmarsh$400$361.73 +2.5%Sep 22, 2026
UBSAnalyst unavailable$415$338.06 +6.3%Sep 9, 2026
Evercore ISIAnalyst unavailable$425$333.12 +8.9%Jul 27, 2026
See 25 more

Track every rating change on WST the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies.…

Historical context

All WST earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the WST recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-24T18:10:56.171651+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-24T18:10:56.168727+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-24. For educational purposes only; not investment advice.